Back to discover
Disease
Gastroesophageal Reflux
Late-stage therapeutic developmentEmerging research
2
Publications
20
Clinical trials
12
Associated genes
6
Related proteins
2018
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Clinical trial2026-07-29Status changed to Completed · ClinicalTrials.gov
Clinical trial2026-07-27Status changed to Completed · ClinicalTrials.gov
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q4 2026.
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20272026-04-13
Major clinical milestoneImportant
Primary completion2026-08-01
Clinical MilestonesViewHide
Results expected
- 2026-04-13Treatment Protocol for the Compassionate Use of DomperidoneResults expected Q4 2027
- 2025-11-20Treatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled TrialResults expected Q4 2026
Recently completed
- 2026-08-01A Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Study to Evaluate the Efficacy and Safety of 2 Doses of Linaprazan Glurate Compared to Lansoprazole in 4 or 8 Weeks Healing in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to DPrimary completion
- 2026-08-01Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux DiseasePrimary completion
- 2026-06-01A Multicenter, RandoMized, Double-blind, Parallel-grOup, Afluxin® Stick Pack vs. Inactive contRol Clinical Investigation to Evaluate the Performance and Safety in Patients With Gastroesophageal Reflux Disease (GERD)Primary completion
- 2025-11-30Multicenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole: TOP-GERDPrimary completion
Activity timeline7
- 2028-12-01ClinicalA Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Linaprazan Glurate Compared to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to DWithdrawn
- 2026-08-01ClinicalA Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Study to Evaluate the Efficacy and Safety of 2 Doses of Linaprazan Glurate Compared to Lansoprazole in 4 or 8 Weeks Healing in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to DPrimary completion
- 2026-08-01ClinicalClinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux DiseasePrimary completion
- 2026-06-01ClinicalA Multicenter, RandoMized, Double-blind, Parallel-grOup, Afluxin® Stick Pack vs. Inactive contRol Clinical Investigation to Evaluate the Performance and Safety in Patients With Gastroesophageal Reflux Disease (GERD)Primary completion
- 2026-04-13ClinicalTreatment Protocol for the Compassionate Use of DomperidoneResults expected Q4 2027
- 2025-11-30ClinicalMulticenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole: TOP-GERDPrimary completion
- 2025-11-20ClinicalTreatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled TrialResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Clinical programme
20
6
17
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes1
- Gastroesophageal Reflux1
Leading journals2
- Gut1
- Journal of pediatric gastroenterology and nutrition1
Leading researchers8
- Bredenoord AJ1
- Cabana M1
- DiLorenzo C1
- Fox MR1
- Gottrand F1
- Gupta S1
- Gyawali CP1
- Kahrilas PJ1
Affiliations (unnormalised)6
- Academic Medical Center1
- Barts and The London School of Medicine and Dentistry1
- Bordeaux University Hospital1
- Catholic University of Leuven1
- Center for Motility and Functional Gastrointestinal Disorders1
- Clinic for Gastroenterology and Hepatology1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.